Strategic Advisory: Opportunities in the Biopharma SHAKTI Transition

1. Executive Summary

• The Regulatory Shift: The Biopharma SHAKTI initiative, backed by a ₹10,000 crore five-year outlay (Union Budget 2026-27), signals the end of India’s reliance on chemical generics. The policy environment now prioritizes high-value biologics through state-funded infrastructure and specialized approval cadres.
• The Operational Imperative: Regulatory harmonization under CDSCO has compressed market authorization to <150 days. To qualify, manufacturers must adopt Non-Animal Methodologies (NAMs) and demonstrate "totality of evidence" in molecular characterization.
• The Pricing Value-Cliff: The NPPA has instituted a mandatory 50% price reduction upon patent expiry for scheduled biologics. Preserving margins requires leveraging Paragraph 32(ii) of the DPCO 2013 to secure 5-year price control immunity for process-patented innovations.
• Capital Allocation Strategy: Transitioning to biologics requires massive CapEx. Enterprises should favor Inorganic Growth (M&A or Biologics CDMO partnerships) over internal builds to mitigate …